Menu Search
Equities

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd

  • Add to watchlist
  • Add to portfolio
  • Add an alert
1349:HKG.HZ

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd

Actions
  • Price (HKD)3.29
  • Today's Change0.00 / 0.00%
  • Shares traded1.34m
  • 1 Year change+32.66%
  • Beta0.8070
Data delayed at least 15 minutes, as of Feb 13 2026 08:08 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd is a China-based company mainly engaged in research and development, manufacturing and marketing of biomedicine. The Company's products include aminolevulinic acid hydrochloride topical powder (trade name: ALA) and hemporfin or injection (trade name: FuMeiDa), and doxorubicin hydrochloride liposome injection (trade name: LIBOd), among others. Its products are mainly used for skin venereal disease treatment and anti-tumor treatment. The Company conducts its businesses in the domestic market.

  • Revenue in HKD (TTM)805.06m
  • Net income in HKD-70.90m
  • Incorporated1996
  • Employees925.00
  • Location
    Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co LtdZhangjiang Hi-tech ParkNo.308 Cailun RoadPudong District, Zhangjiang Hi-tech ParkSHANGHAI 201210ChinaCHN
  • Phone+86 2 158553583
  • Fax+86 2 158553893
  • Websitehttp://www.fd-zj.com
More ▼

Institutional shareholders

0.80%Per cent of shares held by top holders
HolderShares% Held
Dimensional Fund Advisors LPas of 05 Feb 20261.90m0.58%
Invesco Hong Kong Ltd.as of 30 Jan 2026379.00k0.12%
Wanjia Asset Management Co., Ltd.as of 30 Jun 2025164.00k0.05%
Nuode Asset Management Co., Ltd.as of 30 Jun 2025150.00k0.05%
DFA Australia Ltd.as of 30 Nov 20254.37k0.00%
More ▼
Data from 30 Jun 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.